Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation. The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety and fear-related behaviors in humans and experimental animals. The heterogeneity of cannabis-induced psychological outcomes reflects a complex network of molecular interactions between the key neurobiological substrates of anxiety and fear and the endogenous cannabinoid system, mainly consisting of the arachidonic acid derivatives anandamide and 2-arachidonoylglycerol (2-AG) and two receptors, respectively termed CB1 and CB2. The high degree of interindividual variability in the responses to cannabis is contributed by a wide spectrum of factors, including genetic and environmental determinants, as well as differences in the relative concentrations of THC and other alkaloids (such as cannabidiol) within the plant itself. The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and highlights the challenges that should be overcome to harness the therapeutic potential of some of these compounds, all the while limiting the side effects associated with cannabis consumption. In addition the article presents some promising patents on cannabinoid-related agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“Both objectives were met around 30 years later, with the characterization of the two major cannabinoid receptors, CB1 [29] and CB2 [30] as well as the discovery of two most prominent endocannabinoids Narachidonoylethanolamine (commonly named anandamide from the Sanskrit ānanda, bliss) [31] and 2-arachidonoylglycerol (…”
BackgroundCannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“[37-41].”
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“[37-41].”
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 17×
“The prototypical FAAH inhibitor URB597 (Fig.”
BackgroundInfluentialEndogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607 · cited 1×
“Presynaptic CB1 receptors are posited to serve critical functions for the regulation of synaptic plasticity and neurotransmitter release; in particular, they mediate the depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE), consisting in the reduction of γ-a…”
BackgroundImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 1×
“CB1 receptors are typically located on presynaptic terminals [42,43], but they have also been identified in postsynaptic locations [44,45].”
BackgroundIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 1×
“4) has been shown to reduce anxiety-like behaviors in rats, in a rimonabant-sensitive fashion [155,163,215-217].”
BackgroundKatona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 1×
“The bidirectional action of CB1 receptors on anxiety responses may be related to the modulatory role of these targets on GABA and glutamate release across amygdala and other forebrain areas [41,165,166].”
BackgroundEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“The significant increase in anxiety, depression and suicidality in patients under treatment with rimonabant [176-179], in particular, led to the withdrawal of the drug from the European market in October, 2008.”
BackgroundChemical constituents of marijuana: The complex mixture of natural cannabinoids
ElSohly, M. A., & Slade, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.011 · Cited by 1,094 · cited 2×
“The three species included in the Cannabis genus (or sub-species, depending on the taxonomic classification; see [3], for a detailed discussion on the issue), sativa, indica and ruderalis, feature at least 85 unique terpenophenolic compounds, collectively named phytocannabinoids [4].”
BackgroundGlass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052 · cited 1×
“[37-41].”
Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039 · cited 1×
“It is produced from 1,2diacylglycerol (DAG) by diacylglycerol lipase (DAGL) [77] and degraded mainly by the cytosolic serine hydrolase monoacylglycerol lipase (MAGL) [78], although other enzymes are known to contribute to this process [79].”
BackgroundCannabis use and mental health in young people: cohort study.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., & Hall, W. (2002) · BMJ · doi:10.1136/bmj.325.7374.1195 · Cited by 997
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 1×
“Notably, the behavioral outcomes of CBD do not appear to be only due to potential pharmacodynamic/pharmacokynetic competition with THC; indeed, recent studies have shown that CBD exerts inherent anxiolytic effects, both in rodent models [157,198-201] and, more recently, in patients affected by social phobia [202,203].”
BackgroundDistribution of cannabinoid receptors in the central and peripheral nervous system
Mackie, K. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_10 · Cited by 744 · cited 1×
“CB1 receptors are typically located on presynaptic terminals [42,43], but they have also been identified in postsynaptic locations [44,45].”
BackgroundBhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 1×
“The bidirectional action of CB1 receptors on anxiety responses may be related to the modulatory role of these targets on GABA and glutamate release across amygdala and other forebrain areas [41,165,166].”
BackgroundAction of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · cited 2×
“Notably, the behavioral outcomes of CBD do not appear to be only due to potential pharmacodynamic/pharmacokynetic competition with THC; indeed, recent studies have shown that CBD exerts inherent anxiolytic effects, both in rodent models [157,198-201] and, more recently, in patients affected by social phobia [202,203].”
BackgroundSpecificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence
Buckner, J. D., Schmidt, N. B., Lang, A. R., Small, J. W., Schlauch, R. C., & Lewinsohn, P. M. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.01.002 · Cited by 506 · cited 1×
“The latter interpretation is supported by the observation that anxiety-spectrum disturbances and traumas in early developmental stages are a strong predictor for later cannabis use disorders [124-127]; furthermore, several lines of evidence suggest that the anxiolytic effects of THC may partially account for the high…”
BackgroundPatel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 2×
“In contrast with THC, CBD is not psychotropic, but has nevertheless been shown to play a role in the modulation of behavioral effects of cannabis [11].”
BackgroundAntianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · cited 2×
“Notably, the behavioral outcomes of CBD do not appear to be only due to potential pharmacodynamic/pharmacokynetic competition with THC; indeed, recent studies have shown that CBD exerts inherent anxiolytic effects, both in rodent models [157,198-201] and, more recently, in patients affected by social phobia [202,203].”
BackgroundCampos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · cited 1×
“5-HT1A receptors in the dorsal periaqueductal gray, a critical area for the modulation of emotional reactivity to stress [208,209].”
BackgroundWittchen, H.-U., Fröhlich, C., Behrendt, S., Günther, A., Rehm, J., Zimmermann, P., Lieb, R., & Perkonigg, A. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.12.013 · Cited by 311 · cited 1×
“The latter interpretation is supported by the observation that anxiety-spectrum disturbances and traumas in early developmental stages are a strong predictor for later cannabis use disorders [124-127]; furthermore, several lines of evidence suggest that the anxiolytic effects of THC may partially account for the high…”
BackgroundDifferential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling
Azad, S. C., Monory, K., Marsicano, G., Cravatt, B. F., Lutz, B., Zieglgänsberger, W., & Rammes, G. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2134-04.2004 · Cited by 263
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001640 · Cited by 257
Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., & Romero, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-06.2007 · Cited by 256
Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents
Brenneisen, R. (2007) · Forensic Science And Medicine · doi:10.1007/978-1-59259-947-9_2 · Cited by 251 · cited 1×
“A detailed description of the instrumental methods used for classification and source tracing of Cannabis products (including DNA identification for forensic and intelligence purposes) is beyond the scope of this review, but can be found in [5-7].”
MethodHaller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241 · cited 1×
“In agreement with human evidence, preclinical studies have elucidated that the acute administration of low doses of CB1 receptor agonists elicits anxiolytic-like in approach/avoidance tasks [152-156]; conversely, high concentrations of the same compounds are generally associated with the opposite outcomes [157-162] (f…”
ResultFegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230 · cited 2×
“Following release and activation of CB receptors, anandamide is rapidly removed from the synaptic cleft by a carrier-mediated system [69-72] and subsequently hydrolyzed by the membrane enzyme fatty acid amide hydrolase (FAAH) [73-75].”
BackgroundAnxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207 · cited 2×
“The anxiolytic action of CBD may be linked to 5-HT1A receptor, but not through benzodiazepine receptors [204].”
BackgroundKlein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L. E., Huang, X.-F., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2342-0 · Cited by 206
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179 · cited 2×
“Similarly to the effects described for FAAH inhibitors (see above), the anxiolytic effects of this compound were observed in highly aversive (or anxiogenic) contextual settings [229].”
BackgroundKinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.002 · Cited by 170
Strakowski, S. M., DelBello, M. P., Fleck, D. E., Adler, C. M., Anthenelli, R. M., Keck, P. E., Arnold, L. M., & Amicone, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.57 · Cited by 165 · cited 1×
“Of note, chronic consumption of cannabis has been hypothesized to exacerbate depressive or anxious manifestations, and reduce the therapeutic efficacy of anxiolytic agents [122,136-138]; an interesting theoretical implication of this finding is that long-term exposure to cannabinoid agents may lead to profound alterat…”
BackgroundPatel, S., Cravatt, B. F., & Hillard, C. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300535 · Cited by 164
Houston, J. E., Murphy, J., Adamson, G., Stringer, M., & Shevlin, M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm127 · Cited by 162
Haller, J., Barna, I., Barsvari, B., Gyimesi Pelczer, K., Yasar, S., Panlilio, L. V., & Goldberg, S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1494-7 · Cited by 159
García-Gutiérrez, M. S., & Manzanares, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379507 · Cited by 153
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
Casarotto, P. C., Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833b33c5 · Cited by 141 · cited 1×
“Notably, the behavioral outcomes of CBD do not appear to be only due to potential pharmacodynamic/pharmacokynetic competition with THC; indeed, recent studies have shown that CBD exerts inherent anxiolytic effects, both in rodent models [157,198-201] and, more recently, in patients affected by social phobia [202,203].”
BackgroundThe Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety
FABRE, L. F., & McLENDON, D. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02617.x · Cited by 138 · cited 1×
“In line with these premises, early studies showed a robust anxiolytic efficacy of low-dose nabilone in comparison with placebo [144,145].”
ResultSubjective and Physiological Effects After Controlled Sativex and Oral THC Administration
Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.318 · Cited by 117 · cited 1×
“However, recent preliminary clinical studies have shown that this formulation did not significantly reduce anxiety (in fact, it was reported to induce a mild, yet not significant increase of this symptom) [234,235], and that CBD did not appear to elicit a significant opposition to the effect of dronabinol [235], plaus…”
BackgroundSoares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112
Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., & Inghilleri, M. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181633497 · Cited by 109 · cited 1×
“However, recent preliminary clinical studies have shown that this formulation did not significantly reduce anxiety (in fact, it was reported to induce a mild, yet not significant increase of this symptom) [234,235], and that CBD did not appear to elicit a significant opposition to the effect of dronabinol [235], plaus…”
BackgroundChapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83 · cited 2×
“4) has been shown to reduce anxiety-like behaviors in rats, in a rimonabant-sensitive fashion [155,163,215-217].”
BackgroundEffects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain
Liu, C., & Walker, J. M. (2006) · Journal of Neurophysiology · doi:10.1152/jn.00498.2006 · Cited by 37 · cited 1×
“phospholipases [66-68].”
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7 · cited 5×
“4) has been shown to reduce anxiety-like behaviors in rats, in a rimonabant-sensitive fashion [155,163,215-217].”
BackgroundResultInfluentialSelf-citation
Cited by
New approaches and challenges to targeting the endocannabinoid system
Di Marzo, V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users
Bonn-Miller, M. O., Boden, M. T., Bucossi, M. M., & Babson, K. A. (2014) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.821477 · Cited by 281
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol
Sultan, S. R., Millar, S. A., England, T. J., & O'Sullivan, S. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00081 · Cited by 95
Endocannabinoid signaling in social functioning: an RDoC perspective
Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.169 · Cited by 62
Metadata
- Authors
- Tambaro, S., & Bortolato, M.
- Venue
- Recent Patents on CNS Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-04-01
- Volume
- 7
- Issue
- 1
- Pages
- 25-40
- ISSN
- 1574-8898 (ISSN-L)
- OpenAlex
- W1993041600
- Cited by
- 89
- References
- 56
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.